FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229074495> ?p ?o ?g. }

• W4229074495 endingPage "3429" @default.
• W4229074495 startingPage "3419" @default.
• W4229074495 abstract "The phase III ACHIEVE trial conducted in Japan was one of six prospective studies included in the International Duration Evaluation of Adjuvant Therapy collaboration, which explored whether 3 months of adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or capecitabine and oxaliplatin (CAPOX) therapy would be noninferior to 6 months of treatment in patients with curatively resected stage III colon cancer. We report the final analyses of survival and long-term safety.Eligible patients were randomly assigned (1:1) to either 3 or 6 months of adjuvant chemotherapy (modified [m]FOLFOX6 or CAPOX, as selected by the treating physician). Random assignment was stratified according to number of involved lymph nodes, center, regimen, primary site, and age. The primary end point was disease-free survival, assessed in the modified intention-to-treat population. Overall survival (OS) was a secondary end point.The modified intention-to-treat population comprised 1,291 patients: 641 in the 6-month treatment group and 650 in the 3-month treatment group. Median follow-up for this analysis was 74.7 months. Five-year OS rates were comparable: 87.0% in the 3-month treatment group and 86.4% in the 6-month treatment group (hazard ratio, 0.91; 95% CI, 0.69 to 1.20; P = .51). Subgroup analysis of OS did not reveal a significant interaction between baseline characteristics and treatment duration. Peripheral sensory neuropathy lasting longer than 5 years was more common in the 6- compared with 3-month treatment group (16% v 8%, respectively), and in those receiving mFOLFOX6 compared with CAPOX (14% v 11%, respectively).In Asian patients, shortening adjuvant therapy duration from 6 to 3 months did not compromise efficacy and reduced the rate of long-lasting peripheral sensory neuropathy. In this setting, 3 months of CAPOX therapy is an appropriate adjuvant treatment option." @default.
• W4229074495 created "2022-05-08" @default.
• W4229074495 creator A5001002762 @default.
• W4229074495 creator A5002888194 @default.
• W4229074495 creator A5015711180 @default.
• W4229074495 creator A5017077609 @default.
• W4229074495 creator A5018914378 @default.
• W4229074495 creator A5022410093 @default.
• W4229074495 creator A5024191005 @default.
• W4229074495 creator A5024904484 @default.
• W4229074495 creator A5026639791 @default.
• W4229074495 creator A5028506413 @default.
• W4229074495 creator A5028829335 @default.
• W4229074495 creator A5035125935 @default.
• W4229074495 creator A5048365357 @default.
• W4229074495 creator A5054543898 @default.
• W4229074495 creator A5058315816 @default.
• W4229074495 creator A5058441704 @default.
• W4229074495 creator A5062438655 @default.
• W4229074495 creator A5062748030 @default.
• W4229074495 creator A5063723368 @default.
• W4229074495 creator A5067647817 @default.
• W4229074495 creator A5069791653 @default.
• W4229074495 creator A5079883757 @default.
• W4229074495 creator A5087398756 @default.
• W4229074495 date "2022-10-10" @default.
• W4229074495 modified "2023-10-16" @default.
• W4229074495 title "Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial" @default.
• W4229074495 cites W2042038698 @default.
• W4229074495 cites W2061842312 @default.
• W4229074495 cites W2100258195 @default.
• W4229074495 cites W2118950501 @default.
• W4229074495 cites W2138985803 @default.
• W4229074495 cites W2144495943 @default.
• W4229074495 cites W2153625933 @default.
• W4229074495 cites W2169925647 @default.
• W4229074495 cites W2171232394 @default.
• W4229074495 cites W2795004907 @default.
• W4229074495 cites W2801386470 @default.
• W4229074495 cites W2935820515 @default.
• W4229074495 cites W2972815950 @default.
• W4229074495 cites W3043680095 @default.
• W4229074495 cites W3046103354 @default.
• W4229074495 cites W3110292103 @default.
• W4229074495 cites W4211121451 @default.
• W4229074495 cites W4211133582 @default.
• W4229074495 doi "https://doi.org/10.1200/jco.21.02628" @default.
• W4229074495 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35512259" @default.
• W4229074495 hasPublicationYear "2022" @default.
• W4229074495 type Work @default.
• W4229074495 citedByCount "10" @default.
• W4229074495 countsByYear W42290744952022 @default.
• W4229074495 countsByYear W42290744952023 @default.
• W4229074495 crossrefType "journal-article" @default.
• W4229074495 hasAuthorship W4229074495A5001002762 @default.
• W4229074495 hasAuthorship W4229074495A5002888194 @default.
• W4229074495 hasAuthorship W4229074495A5015711180 @default.
• W4229074495 hasAuthorship W4229074495A5017077609 @default.
• W4229074495 hasAuthorship W4229074495A5018914378 @default.
• W4229074495 hasAuthorship W4229074495A5022410093 @default.
• W4229074495 hasAuthorship W4229074495A5024191005 @default.
• W4229074495 hasAuthorship W4229074495A5024904484 @default.
• W4229074495 hasAuthorship W4229074495A5026639791 @default.
• W4229074495 hasAuthorship W4229074495A5028506413 @default.
• W4229074495 hasAuthorship W4229074495A5028829335 @default.
• W4229074495 hasAuthorship W4229074495A5035125935 @default.
• W4229074495 hasAuthorship W4229074495A5048365357 @default.
• W4229074495 hasAuthorship W4229074495A5054543898 @default.
• W4229074495 hasAuthorship W4229074495A5058315816 @default.
• W4229074495 hasAuthorship W4229074495A5058441704 @default.
• W4229074495 hasAuthorship W4229074495A5062438655 @default.
• W4229074495 hasAuthorship W4229074495A5062748030 @default.
• W4229074495 hasAuthorship W4229074495A5063723368 @default.
• W4229074495 hasAuthorship W4229074495A5067647817 @default.
• W4229074495 hasAuthorship W4229074495A5069791653 @default.
• W4229074495 hasAuthorship W4229074495A5079883757 @default.
• W4229074495 hasAuthorship W4229074495A5087398756 @default.
• W4229074495 hasBestOaLocation W42290744951 @default.
• W4229074495 hasConcept C121608353 @default.
• W4229074495 hasConcept C126322002 @default.
• W4229074495 hasConcept C141071460 @default.
• W4229074495 hasConcept C168563851 @default.
• W4229074495 hasConcept C202953159 @default.
• W4229074495 hasConcept C203092338 @default.
• W4229074495 hasConcept C207103383 @default.
• W4229074495 hasConcept C2777909004 @default.
• W4229074495 hasConcept C2777982462 @default.
• W4229074495 hasConcept C2778260052 @default.
• W4229074495 hasConcept C2780456651 @default.
• W4229074495 hasConcept C2780962732 @default.
• W4229074495 hasConcept C2781413609 @default.
• W4229074495 hasConcept C2908647359 @default.
• W4229074495 hasConcept C44249647 @default.
• W4229074495 hasConcept C526805850 @default.
• W4229074495 hasConcept C71924100 @default.
• W4229074495 hasConcept C99454951 @default.
• W4229074495 hasConceptScore W4229074495C121608353 @default.
• W4229074495 hasConceptScore W4229074495C126322002 @default.

• next